Latest News - DexCom
Top Corporates Hub
DexCom
The 5 Most Interesting Analyst Questions From DexCom’s Q4 Earnings Call
19.02.2026 05:38
DexCom’s fourth quarter results reflected ongoing momentum in both product innovation and international expansion. Management attributed the quarter’s performance to the broad rollout of the G7 15-day sensor system in the U.S., which generated positive initial feedback from both customers and physicians due to improved wear time and accuracy. Operational improvements in manufacturing and logistics, such as reestablishing more efficient ocean shipping routes and addressing prior sensor deployment
Medtronic Posts Better-Than-Expected Earnings. Here’s Why the Stock Is Falling.
17.02.2026 13:00
Medical device maker Medtronic reported quarterly earnings and net sales that topped consensus views. Medtronic on Tuesday posted fiscal third-quarter adjusted earnings of $1.36 a share, narrowly beating analysts’ forecasts of $1.34. Medtronic’s profit declined from the same period last year on a non-adjusted basis, slipping to $1.14 billion from $1.29 billion.
DexCom Inc. (DXCM) Reports Strong Performance While Maintaining Forward Outlook
15.02.2026 11:52
DexCom Inc. (NASDAQ:DXCM) is one of the best medical technology stocks to invest in. On February 12, DexCom Inc. (NASDAQ:DXCM) shared its Q4 2025 earnings and reported $1.26 billion in quarterly revenue. This was well ahead of the $1.25 billion that Wall Street expected, and a 13% year over year growth. According to management, this […]
DexCom Stock Falls Despite Q4 Earnings Beat, G7 Rollout Drives Growth
13.02.2026 17:35
DXCM beats Q4 EPS estimates, posts 13% revenue growth and reiterates 2026 guidance as G7 15 Day rollout and margin gains drive momentum.
Dexcom reports 2025 revenues of $4.66bn yet 2026 outlook lags analyst expectations
13.02.2026 17:10
Dexcom's 2026 revenue estimates lagged analysts' expectations, according to data compiled by the London Stock Exchange Group (LSEG).
Why Is DexCom (DXCM) Stock Rocketing Higher Today
13.02.2026 16:31
Shares of medical device company DexCom (NASDAQ:DXCM) jumped 7.3% in the morning session after it reported better-than-expected fourth-quarter 2025 financial results, beating analyst estimates for both revenue and earnings.
Dexcom seeks expanded Medicare coverage of CGMs for Type 2 diabetes
13.02.2026 11:38
New CEO Jake Leach said the company plans a trial readout in mid-2026 to support coverage of its glucose sensors in Type 2 users who don’t take insulin.
Mizuho Maintains Outperform on DexCom, Raises Price Target to $90
13.02.2026 09:36
Mizuho analyst Anthony Petrone maintains DexCom (NASDAQ:DXCM) with a Outperform and raises the price target from $78 to $90.
DXCM Q4 Deep Dive: New Product Launches and International Strategy Drive Outlook
13.02.2026 05:35
Medical device company DexCom (NASDAQ:DXCM) reported Q4 CY2025 results beating Wall Street’s revenue expectations, with sales up 13.1% year on year to $1.26 billion. The company expects the full year’s revenue to be around $5.21 billion, close to analysts’ estimates. Its non-GAAP profit of $0.68 per share was 4.5% above analysts’ consensus estimates.
DexCom Inc (DXCM) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Expansions
13.02.2026 05:04
DexCom Inc (DXCM) reports a 13% revenue increase, unveils strategic plans for international growth, and anticipates future challenges in expanding coverage for type 2 non-insulin users.
DexCom Stelo AI Upgrade Aims To Deepen Consumer Metabolic Health Engagement
12.02.2026 08:09
DexCom (NasdaqGS:DXCM) announced new AI-enabled features for its Stelo glucose monitoring system. The update adds a comprehensive nutrition database, expanded meal tracking, and personalized behavioral insights. The enhancements are designed to support users focused on metabolic health and broader wellness goals. DexCom, best known for continuous glucose monitoring in diabetes care, is extending its reach further into consumer health with Stelo. By tying real time glucose data to structured...
Medical Device Stocks to Report Earnings on Feb. 12: BAX, WST & DXCM
11.02.2026 16:00
BAX, WST & DXCM gear up for Q4 earnings amid macro pressure, steady revenue growth and AI-driven demand.
What Are Wall Street Analysts' Target Price for DexCom Stock?
11.02.2026 14:31
Despite DexCom’s weak performance relative to the broader market over the past year, Wall Street analysts remain bullish about the stock’s prospects.
Earnings To Watch: DexCom (DXCM) Reports Q4 Results Tomorrow
11.02.2026 03:12
Medical device company DexCom (NASDAQ:DXCM) will be reporting earnings this Thursday after market hours. Here’s what you need to know.
Wearables’ future in healthcare likely to hinge on actionable insights
06.02.2026 12:42
Wearables in healthcare must advance to a stage where they provide actionable insights in addition to datapoints.
Stelo Adds Enhanced Smart Meal Logging Features as Dexcom Continues to Transform Personal Glucose Management
04.02.2026 13:30
SAN DIEGO, February 04, 2026--Dexcom, Inc. (Nasdaq:DXCM), the global leader in glucose biosensing, announced it will roll out an advanced AI-enabled enhancement to Stelo that will transform how users understand their glucose health and take steps in achieving their long-term health goals. The newest features will launch nationwide in the coming weeks.
DexCom’s Q4 Beat And 2026 Targets Tested By Rising CGM Competition
01.02.2026 06:07
DexCom reported strong preliminary Q4 results, with topline figures above its earlier expectations. The company paired this update with a positive outlook for 2026, outlining targets that support its longer term growth plans. These announcements come as competition in glucose monitoring intensifies and recent analyst views on NasdaqGS:DXCM have turned more mixed. DexCom, traded as NasdaqGS:DXCM, last closed at $73.04. The stock is up 9.8% over the past month and 9.8% year to date, but it...
What DexCom (DXCM)'s Strong Q4 Beat and 2026 Margin Guidance Means For Shareholders
01.02.2026 02:09
DexCom recently reported preliminary fourth-quarter results showing year-over-year revenue growth in both U.S. and international markets, beating consensus expectations and pairing this with guidance for higher 2026 revenue and improved adjusted margins. This stronger operational outlook has prompted many analysts to reiterate positive ratings even as some highlight rising competition in DexCom’s core insulin-intensive segments. Next, we’ll examine how DexCom’s upbeat 2026 guidance for...
Senseonics wins CE mark for one-year CGM
30.01.2026 10:00
The company is hiring sales reps and transitioning staff from its former partner to support launches in Germany, Italy, Spain and Sweden.